U.S. markets close in 1 hour 15 minutes
  • S&P 500

    3,855.87
    +56.96 (+1.50%)
     
  • Dow 30

    31,177.16
    +246.64 (+0.80%)
     
  • Nasdaq

    13,477.29
    +280.12 (+2.12%)
     
  • Russell 2000

    2,154.19
    +3.05 (+0.14%)
     
  • Crude Oil

    53.28
    +0.30 (+0.57%)
     
  • Gold

    1,867.30
    +27.10 (+1.47%)
     
  • Silver

    25.88
    +0.56 (+2.19%)
     
  • EUR/USD

    1.2108
    -0.0025 (-0.21%)
     
  • 10-Yr Bond

    1.0890
    -0.0030 (-0.27%)
     
  • GBP/USD

    1.3645
    +0.0011 (+0.08%)
     
  • USD/JPY

    103.5680
    -0.3240 (-0.31%)
     
  • BTC-USD

    34,984.84
    +584.87 (+1.70%)
     
  • CMC Crypto 200

    692.40
    -8.22 (-1.17%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,523.26
    -110.20 (-0.38%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2021 - ICPT

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - December 23, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Intercept Pharmaceuticals, Inc. ("Intercept") (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get more information go to:

https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11785&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Intercept you have until January 4, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70960